

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

CAL-120

RRID:CVCL_1104

Type: Cell Line

Proper Citation

RRID:CVCL_1104

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1104

Proper Citation: RRID:CVCL_1104

Description: Cell line CAL-120 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast carcinoma

Defining Citation: [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30613774](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CAL-120

Synonyms: CAL 120, CAL120

Cross References: CLO:CLO_0002179, EFO:EFO_0005356, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-6647, BioGRID_ORCS_Cell_line:166, BioSample:SAMN03472991, BioSample:SAMN03473555, BioSample:SAMN10989564, cancercellines:CVCL_1104, Cell_Model_Passport:SIDM00940, ChEMBL-Cells:ChEMBL3308577, ChEMBL-Targets:ChEMBL1075405, Cosmic:906826,

Cosmic:1995355, Cosmic:2164984, Cosmic-CLP:906826, DepMap:ACH-000212, DSMZ:ACC-459, DSMZCellDive:ACC-459, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906826, GEO:GSM274647, GEO:GSM274665, GEO:GSM344361, GEO:GSM344411, GEO:GSM783963, GEO:GSM827160, GEO:GSM843483, GEO:GSM847210, GEO:GSM847455, GEO:GSM886904, GEO:GSM887969, GEO:GSM1172944, GEO:GSM1669645, IARC_TP53:21208, LiGeA:CCLE_802, LINCS_HMS:51110, LINCS_LDP:LCL-1463, Pharmacodb:CAL120_165_2019, PRIDE:PXD030304, Progenetix:CVCL_1104, PubChem_Cell_line:CVCL_1104, SLKBase:3487, Wikidata:Q54808384

ID: CVCL_1104

Record Creation Time: 20220427T215438+0000

Record Last Update: 20260913T002306+0000

Ratings and Alerts

No rating or validation information has been found for CAL-120.

No alerts have been found for CAL-120.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Thatikonda V, et al. (2024) Genetic dependencies associated with transcription factor activities in human cancer cell lines. Cell reports, 43(5), 114175.

- Ackermann T, et al. (2024) Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis. *EMBO molecular medicine*, 16(11), 2749.
- Paulson AL, et al. (2024) Discovery, Validation and Mechanistic Study of XPO1 Inhibition in the Treatment of Triple-Negative Breast Cancer. *Cancers*, 16(23).
- K??ferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.
- Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.
- Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell chemical biology*, 27(10), 1229.
- Johnstone CN, et al. (2020) FGF13 promotes metastasis of triple-negative breast cancer. *International journal of cancer*, 147(1), 230.
- Yomtoubian S, et al. (2020) Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. *Cell reports*, 30(3), 755.
- Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.
- Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. *Cell reports*, 28(9), 2331.
- Wu Q, et al. (2019) A chemical toolbox for the study of bromodomains and epigenetic signaling. *Nature communications*, 10(1), 1915.
- Hafner M, et al. (2019) Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. *Cell chemical biology*, 26(8), 1067.
- Heijink AM, et al. (2019) Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. *Cell reports*, 28(9), 2345.
- Zwang Y, et al. (2017) Synergistic interactions with PI3K inhibition that induce apoptosis. *eLife*, 6.
- Muir A, et al. (2017) Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. *eLife*, 6.
- Malek M, et al. (2017) PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. *Molecular cell*, 68(3), 566.